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ABSTRACT
Evidence suggests that inflammation plays
a central role in the pathogenesis of
atherosclerosis (Libby, Nature 420:868–874,
2002). Inflammation is a physiologic process
with highly regulated and often redundant
mechanisms to balance pro-inflammatory and
anti-inflammatory responses. The complexity of
these networks has made it challenging to identify
those specific pathways or key enzymes that
contribute directly to atherogenesis and could
act as a valuable therapeutic target. Lipoprotein-
associated phospholipase A2 (Lp-PLA2) is a
member of the phospholipase A2 family of
enzymes and is believed to contribute to
atherosclerotic plaque progression and
instability by promoting inflammation. A large
number of epidemiologic studies have
demonstrated that elevated levels of Lp-PLA2 are
associated with an increased risk of cardiovascular
events across diverse patient populations,
independent of established risk factors including
low-density lipoprotein cholesterol. Further, a
growing number of preclinical and genetic
studies support a causal role for Lp-PLA2 in
atherosclerosis. The development of a novel
therapeutic agent that directly inhibits the
Lp-PLA2 enzyme has provided a unique
opportunity to directly test the hypothesis that
inhibition of this inflammatory enzyme will
translate into improved clinical outcomes. In
this article, we will review the evidence to
support the notion that Lp-PLA2 is causally
implicated in the pathobiology of atherogenesis
and discuss the potential utility of inhibiting this
enzyme as a therapeutic target.
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LP-PLA2: BIOLOGIC MECHANISMS
Lipoprotein-associated phospholipase A2 (Lp-
PLA2) is a calcium-independent enzyme that
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circulates in plasma in its constitutively active
form [1, 2]. It is secreted by the inflammatory
cells, including monocyte-derived macrophages,
T cells and mast cells, and circulates primarily
bound to low-density lipoprotein (LDL)
cholesterol. It is a member of the
phospholipase A2 superfamily of enzymes that
are characterized by their ability to hydrolyze
the sn-2 ester bond of phospholipid substrates.
The catalytic activity of Lp-PLA2 is believed to
be lipoprotein-dependent with more of its
activity concentrated on small, dense LDL
cholesterol, including lipoprotein(a) particles,
that are presumed to be the most atherogenic.
Discovered because of its ability to catalyze
the hydrolysis of platelet-activating factor
(PAF), Lp-PLA2 was originally referred to as
PAF-acetylhydrolase before adopting its
current name. Aside from PAF, the enzyme
has specificity for a wide variety of polar
phospholipids, including oxidized and short-
chain phospholipids. Through this action,
Lp-PLA2 is believed to play a key role in
the hydrolysis and depletion of oxidized
phospholipids (oxPL) associated with lipoproteins
[1, 2].
The biologic role of Lp-PLA2 in the
pathogenesis of atherosclerosis continues to be
debated. Initial reports suggested a possible
cardioprotective role for Lp-PLA2 through
degradation of PAF and thereby indirect
inhibition of platelet activation. An anti-
atherogenic role for Lp-PLA2 was also
hypothesized due to its ability to hydrolyze
oxPLs on LDL cholesterol, therefore
theoretically reducing the pathogenicity of
oxidized LDL particles. However, the latter was
not supported by more recent evidence that
suggested that oxPL may in fact play an anti-
inflammatory role and the hydrolysis of these
lipids might, therefore, only contribute to
further inflammation [3].
Overall, the weight of the evidence now
favors a pro-atherogenic role for Lp-PLA2.
Within the atherosclerotic plaque, Lp-PLA2
hydrolyzes oxidized LDL particles leading to
the formation of lysophosphatidylcholine (lyso-
PC) and oxidized nonesterified fatty acids
which are believed to be potent pro-
inflammatory mediators [2]. The production of
these by-products is believed to contribute to
atherogenesis and plaque destabilization
through propagation of the inflammatory
cascade and contributing to endothelial
dysfunction, necrolysis, and apoptosis (Fig. 1).
The culmination of which may lead to the
production of more thin-cap fibroatheromas
(TCFAs), an unstable plaque type that is more
vulnerable to rupture [4]. These assertions are
supported through histological staining that
has shown that the Lp-PLA2 protein appears to
be more concentrated in TCFAs than in smaller
and more stable plaques [5].
In addition, both biologic and animal data
support a pro-atherogenic role for the Lp-PLA2
enzyme. Lp-PLA2 mRNA and protein have
been identified in macrophages in both
human and rabbit atherosclerotic lesions [6].
Hypercholesterolemic pigs have demonstrated
an association between higher levels of Lp-PLA2
enzyme activity, higher levels of oxidized lipids,
and accelerated progression of atherosclerosis.
As well, direct inhibition of Lp-PLA2 activity was
shown to inhibit progression of coronary
atherosclerosis [7]. In humans, Lp-PLA2
expression is upregulated in unstable and
ruptured carotid artery plaques along with
increased concentrations of lysoPC [8].
Moreover, Lp-PLA2 gene expression in
retrieved carotid plaques post endarterectomy
has been shown to be independently associated
with an increased risk of future cardiovascular
(CV) events [9]. In TCFAs, Lp-PLA2 expression
is strongly expressed in macrophages and
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deposition of the Lp-PLA2 protein preferentially
co-localizes with apoptotic macrophages near
the fibrous cap and in the necrotic core, a region
that is abundant in lipids and oxidation
products [5]. In contrast, minimal Lp-PLA2
activity has been identified in thicker capped
or more stable fibroatheromas.
LP-PLA2: EPIDEMIOLOGY AND RISK
STRATIFICATION
Since Lp-PLA2 is an enzyme, it can be quantified
either through assessment of its mass or
activity. Lp-PLA2 mass is typically assessed
through an immunoassay that quantifies the
concentration of Lp-PLA2 in serum or plasma.
The commercially available PLACTM test
(diaDexus, Inc.; San Francisco, CA, USA) is an
enzyme-linked immunosorbent (ELISA) assay
that has been approved by the United States
Food & Drug Administration for the
quantitative determination of Lp-PLA2 and to
be used as an aid for the assessment of risk of
coronary heart disease or ischemic stroke. Since
Lp-PLA2 is highly selective for phospholipids
with very short acyl groups at the sn-2 position,
Lp-PLA2 activity can be measured through
assays that quantify the rate of formation of
the reaction by-product through radiometric or
calorimetric methods. Although early evidence
suggested a high correlation between these two
measures, more recent studies have shown only
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Fig. 1 The proposed effects of Lp-PLA2 on the progression
of atherosclerosis. Lp-PLA2 circulates primarily bound to
low-density lipoprotein (LDL) cholesterol and is most
concentrated in small dense LDL particles. In the
atherosclerotic plaque, it is believed that Lp-PLA2
hydrolyzes modiﬁed phospholipids on oxidized LDL
particles to generate lysophosphatidylcholine (lysoPC) and
oxidized non-esterized free fatty acids (NEFA). In vitro
effects of these compounds include endothelial dysfunction,
chemotaxis, cytokine activation, and cytotoxic effects.
These pro-inﬂammatory mediators are believed to
contribute to atherosclerotic plaque inﬂammation and
instability, thereby leading to further disease progression
and plaque instability. Adapted with permission from
Motiwala and O’Donoghue [30]. Copyright  Saunders,
an imprint of Elsevier Inc. (2011)
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a modest correlation between Lp-PLA2 activity
and mass [10]. It is plausible that the two
measures provide complementary information,
since the Lp-PLA2 mass assay quantifies Lp-PLA2
that is primarily accessible on the lipoprotein
surface, whereas the activity assay may assess
complete Lp-PLA2 activity under denaturing
conditions.
To date, several studies have examined the
prognostic utility of Lp-PLA2 activity and mass
for predicting the risk of CV events in primary
and secondary prevention patient populations.
The West of Scotland Coronary Prevention
Study (WOSCOPS) was the first large-scale
analysis to demonstrate an association
between Lp-PLA2 mass concentration and the
risk of subsequent CV events in hyperlipidemic
men [11]. Importantly, in this study, Lp-PLA2
provided incremental information for risk
stratification that was independent of
established cardiac risk factors, LDL cholesterol
and other markers of risk including C-reactive
protein, fibrinogen, and white blood cell count.
Subsequent to the publication of the
WOSCOPS results, several studies have since
examined the prognostic utility of Lp-PLA2
activity or mass in healthy individuals and in
those with established disease. Although several
studies in primary prevention validated the
previously observed results in WOSCOPS,
other studies did not show an association
between Lp-PLA2 and CV outcomes after
multivariable adjustment [12–14]. In the
Atherosclerosis Risk in Communities (ARIC)
study, an association between Lp-PLA2 and the
risk of future coronary disease was only
demonstrated in those subjects with an LDL
cholesterol \130 mg/dl [15].
The prognostic utility of Lp-PLA2 has also
been examined in individuals with established
coronary disease. Lp-PLA2 activity or mass do
not appear to be useful for risk stratification in
the acute phase of an acute coronary syndrome
(ACS) [1, 10, 16], but Lp-PLA2 activity levels are
associated with an increased risk of CV events
once stabilized a few weeks after the event [10].
It remains incompletely understood why Lp-
PLA2 mass or activity is not associated with the
risk of recurrent CV events when measured
early after ACS. In contrast, a large study that
included 3,766 patients with stable coronary
artery disease (CAD) demonstrated that higher
levels of Lp-PLA2 mass were independently
associated with an increased risk of CV events
[17]. In both stable CAD and in those at least
1 month from an ACS, Lp-PLA2 is only
minimally correlated with C-reactive protein
(CRP) and adds incremental prognostic utility
for prediction of CV events. The Lp-PLA2
Studies Collaboration combined patient-level
data for 32,453 individuals with established
individuals with stable CV disease and found
that Lp-PLA2 was independently associated with
an increased risk of coronary heart disease
(CHD), as well as vascular and non-vascular
death [18].
In all, the Lp-PLA2 Studies Collaboration
report combined data for more than 79,000
subjects across 32 prospective studies in primary
and secondary prevention and demonstrated
that Lp-PLA2 activity and mass both have a
continuous association with the risk of CHD
and vascular death that is similar in magnitude
to non-HDL cholesterol and systolic blood
pressure and is independent of conventional
risk factors [18]. When data were combined
across studies, there existed a strong correlation
between Lp-PLA2 activity and LDL surrogates,
including non-HDL cholesterol (r = 0.49),
apolipoprotein B (r = 0.45), and directly
measured LDL cholesterol (r = 0.48). Lp-PLA2
activity was correlated with log triglyceride
concentration (r = 0.22) and inversely
correlated with HDL cholesterol (r = 0.24). Lp-
128 Cardiol Ther (2013) 2:125–134
123
PLA2 activity was higher in men than in
women; however, only a weak or non-
significant association was observed between
Lp-PLA2 activity and age, systolic blood
pressure, body-mass index, smoking, and CRP.
Overall, similar correlations were observed for
Lp-PLA2 mass and baseline covariates. A slightly
weaker association was observed between Lp-
PLA2 mass and the lipid parameters, whereas a
stronger correlation was observed between Lp-




Although several studies have shown that
higher levels of Lp-PLA2 are associated with an
increased risk of CV events, such studies cannot
demonstrate causality. Genetic variants that
lead to natural alterations in Lp-PLA2 activity
provide a unique opportunity to begin to assess
whether the enzyme may play a causal role in
the development of CV disease. The gene
encoding the Lp-PLA2 protein (PLA2G7) has 12
exons and is located on chromosome 6p21.2-12
[19]. A common loss-of-function (LOF)
mutation (V279F allele) in the Lp-PLA2-
encoding gene (PLA2G7) has been identified
in individuals of Japanese, Chinese, and Korean
descent and leads to natural deficiency or
absence of Lp-PLA2 activity. Those with two
LOF alleles (homozygotes) completely lack Lp-
PLA2 activity, whereas those with one LOF allele
(heterozygotes) have approximately a 50%
reduction in Lp-PLA2 activity, as compared
with those without this variant (wild-type).
Despite initial conflicting reports from
smaller studies, a larger scale study of the
V279F loss-of-function polymorphism supports
a pro-atherogenic role for the Lp-PLA2
enzyme [19]. The study consisted of two large
case–control populations in Korean men and
demonstrated that genetic deficiency in Lp-
PLA2 activity due to carriage of the V279F null
allele was associated with reduced odds of
coronary heart disease. There tended to be a
gene-dose effect such that carriage of a single
copy of the V279F allele was associated with a
21% reduction in the odds of CAD, whereas two
copies were associated with a 31% reduction in
risk of disease. In turn, the magnitude of this
reduction in risk was consistent with what one
would predict based on the epidemiologic data




Since growing evidence supports a pro-
atherogenic role for Lp-PLA2, ongoing research
is investigating its utility as a therapeutic target.
Since Lp-PLA2 circulates primarily bound to
LDL cholesterol, drugs that influence
lipoprotein concentration have been shown to
influence Lp-PLA2 levels, including statins [20,
21], niacin [22], fenofibrate [23], and
gemfibrozil [24]. The cholesteryl ester transfer
protein (CETP) inhibitor dalcetrapib (no longer
in development) was shown in phase II testing
to increase Lp-PLA2 mass by approximately 17%
as compared with placebo [25]. Since Lp-PLA2 is
partly bound to HDL cholesterol, this effect may
be perhaps explained by the marked rise in HDL
cholesterol that is observed with CETP
inhibitors. However, it remains unknown
whether this effect on Lp-PLA2 is a class effect
or if it is specific to dalcetrapib.
Unlike these lipid-modifying agents,
darapladib is an orally active and reversible
direct inhibitor of Lp-PLA2 enzyme activity.
Although other direct inhibitors of Lp-PLA2
are in development, darapladib is the only
Cardiol Ther (2013) 2:125–134 129
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direct Lp-PLA2 inhibitor in phase III testing. In
pre-clinical studies in diabetic and
hypercholesterolemic pigs, darapladib reduced
the necrotic core area and medial destruction,
resulting in fewer lesions with an unstable
phenotype [7]. Importantly, darapladib
inhibited Lp-PLA2 activity both in plasma and
directly within atherosclerotic plaques,
including a corresponding reduction in intra-
plaque lysoPC. Darapladib also led to a
downregulation of inflammatory gene
expression, including 24 genes associated with
T-lymphocyte and macrophage functioning.
Expression of monocyte chemoattractant
protein-1 (MCP-1) chemokine receptor CCR2,
a marker of a subset of pro-inflammatory
macrophages (M1 subtype) that is known to
accumulate in atherosclerotic lesions, was also
reduced. As expected from these gene
expression findings, plaque macrophage
content was reduced with darapladib.
Darapladib did not modify plasma lipid levels,
providing evidence that inhibition of
inflammation without an effect on cholesterol
concentration could diminish inflammation
and reduce development of unstable
atherosclerotic lesions.
DARAPLAPIB: CLINICAL STUDIES
In a dose-ranging phase II study of patients with
stable CHD on a background of atorvastatin (20
or 80 mg daily), darapladib 160 mg daily led to
sustained inhibition of Lp-PLA2 activity by an
average of 66% during 12 weeks of treatment,
regardless of baseline lipid levels [26]. In this
study, darapladib reduced interleukin-6, a
marker of inflammation by 12.3%, but did not
influence C-reactive protein or lipoprotein
concentrations. Although Lp-PLA2 was
originally named based on its ability to
hydrolyze platelet-activating factor, inhibition
of the Lp-PLA2 enzyme has not been shown to
have any effect on platelet function.
The Integrated Biomarker and Imaging
Study-2 (IBIS-2) trial was a randomized,
double-blind, placebo-controlled phase II trial
of darapladib 160 mg daily in high-risk patients
with CHD [27]. All patients were to undergo
intravascular ultrasound with additional
assessment by virtual histology (IVUS-VH) at
baseline and after 12 months. As part of the
study design, subjects were treated with a
background of intensive statin therapy.
Consistent with the results from the dose-
ranging study, darapladib reduced Lp-PLA2
activity by an average of 59% and did not
reduce C-reactive protein concentration. At the
end of 12 months, darapladib halted expansion
of the plaque’s necrotic core, whereas the
necrotic core had expanded in placebo-treated
patients despite the background of statin
therapy. Darapladib did not reduce the
primary endpoint of total atheroma volume
when compared with placebo [27]. In phase II
testing, darapladib was well tolerated except for
a higher incidence of diarrhea, dysgeusia
(distortion of taste sensation), and malodor of
feces and urine [26, 27]. Together, these pre-
clinical and clinical studies support the concept
of Lp-PLA2 inhibition as a therapeutic target for
patients with atherosclerosis.
Currently, the efficacy and safety of
darapladib are being evaluated in two large-
scale, multicenter, double-blind, placebo-
controlled randomized phase III clinical trials
in subjects with stable and unstable coronary
disease (Table 1). The STABILITY (STabilization
of Atherosclerotic plaque By Initiation of
darapLadIb TherapY, ClinicalTrials.gov
identifier: NCT00799903) trial is evaluating
the efficacy and safety of darapladib (160 mg
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daily) in more than 15,800 subjects with stable
coronary disease on a background of evidence-
based therapy [28]. The Stabilization Of pLaques
usIng Darapladib-Thrombolysis in Myocardial
Infarction 52 (SOLID-TIMI 52,
ClinicalTrials.gov identifier: NCT 01000727)
study is evaluating the efficacy and safety of
darapladib (160 mg daily) in more than 13,000
subjects who were enrolled within 30 days of
hospitalization for an acute coronary syndrome,
including unstable angina, non-ST-elevation
myocardial infarction (MI) and ST-elevation
MI [29]. Both trials are event-driven with
anticipated median treatment duration
between 2 and 3 years. Both trials have
completed enrollment and the topline trial
results are anticipated in 2014. Together, these
trials will directly test the hypothesis of whether
Lp-PLA2 plays a causal role in atherogenesis and
is, therefore, a valuable therapeutic target
in patients with stable and unstable
atherosclerotic disease.
CONCLUSION
Inflammation plays a central role in the
development of atherosclerosis and the Lp-
PLA2 enzyme is hypothesized to play a causal
role in its pathogenesis. Epidemiological and
genetic data now support the concept that
Lp-PLA2 may indeed be a risk factor for
the progression of atherosclerotic disease.
Darapladib is a selective inhibitor of the Lp-
PLA2 enzyme that is now being evaluated in two
large-scale phase III clinical trials. The results of
these trials will test whether direct inhibition of
Lp-PLA2 is useful for halting the progression of
atherosclerosis and will provide valuable
insights into the underlying pathobiology of
atherothrombotic events and plaque rupture, in
addition to evaluating the therapeutic utility of
Lp-PLA2 inhibition.
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